Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
复制标题
选择过程对转移性乳腺癌患者接受标准剂量含阿霉素化疗的潜在高剂量化疗候选者的反应率和长期生存的影响。
DOI：
--
复制
发表时间：
1997
影响因子：
45.3
通讯作者：
G. Hortobagyi
中科院分区：
文献类型：
--
作者：
Z. Rahman;D. Frye;A. U. Buzdar;T. L. Smith;Lina Asmar;R. Champlin;G. Hortobagyi
目的
大多数有关转移性乳腺癌高剂量化疗 (HDCT) 的数据都来自 II 期研究。这些数据的解释取决于与在类似情况下接受标准治疗的适当选择的历史对照患者的数据的比较。我们报告了符合 HDCT 条件但接受含阿霉素标准剂量化疗的转移性乳腺癌患者的长期结果。
患者和方法
对 18 个连续的含阿霉素治疗转移性乳腺癌方案前瞻性收集的数据进行了评估。使用 HDCT 的通用资格标准，我们确定了适合 HDCT 的患者。我们分析了所有患者、潜在 HDCT 候选者和非候选者的缓解率、无进展生存期 (PFS) 和总生存期 (OS)。
结果
这 18 项研究共有 1,581 名患者入组。 645 人是 HDCT 候选人，936 人是非候选人。 HDCT 候选人的完全缓解率为 27%，非候选人为 7%；中位 PFS 分别为 16 个月和 8 个月，中位 OS 分别为 30 个月和 17 个月。 HDCT 候选者和非候选者的 5 年生存率分别为 21% 和 6%，10 年生存率分别为 7% 和 2%。
结论
这项研究表明，HDCT 单臂试验的令人鼓舞的结果可能部分归因于选择了预后较好的患者，并进一步强调了完成正在进行的 HDCT 随机试验以评估 HDCT 对转移性乳腺癌患者的相对疗效的重要性。
PURPOSE
Most of the data about high-dose chemotherapy (HDCT) for metastatic breast cancer are derived from phase II studies. The interpretation of these data depends on comparisons with data from properly selected historical control patients treated with standard therapy under similar circumstances. We report the long-term results of patients with metastatic breast cancer who were eligible for HDCT but were treated with doxorubicin-containing standard-dose chemotherapy.
PATIENTS AND METHODS
Prospectively collected data from 18 successive doxorubicin-containing protocols for the treatment of metastatic breast cancer were evaluated. Using common eligibility criteria for HDCT, we identified patients who would have been candidates for HDCT. We analyzed response rates, progression-free survival (PFS), and overall survival (OS) for all patients, potential HDCT candidates, and noncandidates.
RESULTS
A total of 1,581 patients was enrolled onto the 18 studies. Six hundred forty-five were HDCT candidates, and 936 were noncandidates. The complete response rate was 27% for HDCT candidates and 7% for noncandidates; median PFS was 16 and 8 months and median OS was 30 and 17 months, respectively. Survival rates for HDCT candidates and noncandidates, respectively, were 21% and 6% at 5 years and 7% and 2% at 10 years.
CONCLUSION
This study suggests that encouraging results of single-arm trials of HDCT could partially be due to selection of patients with better prognoses and further stresses the importance of completing ongoing randomized trials of HDCT to assess the relative efficacy of HDCT in patients with metastatic breast cancer.
高剂量组合烷化剂准备方案与自体骨髓支持：丹纳法伯癌症研究所/贝斯以色列医院的经验。
DOI：
--
发表时间：
1987
期刊：
Cancer treatment reports
影响因子：
--
作者：
Antman,K;Eder,JP;Elias,A;Shea,T;Peters,WP;Andersen,J;Schryber,S;Henner,WD;Finberg,R;Wilmore,D
通讯作者：
Wilmore,D
大剂量阿霉素治疗晚期乳腺癌的 I-II 期研究。
DOI：
10.1200/jco.1987.5.2.172
发表时间：
1987
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Jones,RB;Holland,JF;Bhardwaj,S;Norton,L;Wilfinger,C;Strashun,A
通讯作者：
Strashun,A
高剂量化疗和自体干细胞支持治疗晚期乳腺癌延长无进展生存期的预后因素。
DOI：
10.1200/jco.1995.13.8.2043
发表时间：
1995
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Ayash,LJ;Wheeler,C;Fairclough,D;Schwartz,G;Reich,E;Warren,D;Schnipper,L;Antman,K;Frei3rd,E;Elias,A
通讯作者：
Elias,A